Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Reformation of the Chondroitin Sulfate Glycocalyx Enables Progression of AR-Independent Prostate Cancer

August 16, 2022

[Nature Communications] Investigators demonstrated that changes in chondroitin sulfate , a major glycosaminoglycan component of the tumor cell glycocalyx and extracellular matrix, was androgen receptor-regulated and promoted the adaptive progression of CRPC after androgen receptor pathway inhibition.

Stem Cells As Target for Prostate Cancer Therapy: Opportunities and Challenges

August 16, 2022

[Stem Cell Reviews and Reports] Scientists explore the relevance of evaluating the TLR3 and P53 status in prostate cancer patients before starting an immunotherapy based on the use of Polyinosinic:Polycytidylic acid +9cRA to determine whether they will be responsive to treatment.

DDX5 mRNA-Targeting Antisense Oligonucleotide as a New Promising Therapeutic in Combating Castration-Resistant Prostate Cancer

August 16, 2022

[Molecular Therapy] Through the identification and analysis of DEAD-box protein 5 (DDX5) protein interaction networks, the authors identified some specific functions of DDX5 in CRPC that could contribute actively to tumor progression and therapeutic resistance.

Osteoclasts Directly Influence Castration-Resistant Prostate Cancer Cells

August 16, 2022

[Clinical & Experimental Metastasis] Osteolytic (PC-3) and osteoblastic (LNCaP-19) castration-resistant prostate cancer (CRPC) cells were co-cultured with mature osteoclasts or their precursor cells to characterize direct effects of mature osteoclasts on CRPC cells.

De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted Peptide PROTAC for Prostate Cancer Therapy

August 16, 2022

[Advanced Science] The authors designed a novel peptide-based proteolysis-targeting chimera drug to induce androgen receptor and androgen receptor splice variant-7 degradation in a DNA binding domain and MDM2-dependent manner.

Griffith Launches Two Cancer Research Centres with $4.6M ACRF Funding

August 15, 2022

[Griffith University] Griffith University has launched two cancer research centres backed by $4.6 million in funding from the Australian Cancer Research Foundation (ACRF) this month.

FOXA1 Inhibits Hypoxia Programs through Transcriptional Repression of HIF1A

August 12, 2022

[Oncogene] Researchers reported that FOXA1 down-regulation induced hypoxia transcriptional programs, and Forkhead Box A1 (FOXA1) level was negatively correlated with hypoxia markers in clinical prostate cancer (PCa) samples.

White Adipose Tissue-Derived Factors and Prostate Cancer Progression: Mechanisms and Targets for Interventions

August 12, 2022

[Cancer and Metastasis Reviews] The authors discuss the role adipose stromal cells, the progenitors to mature adipocytes and other cell types in white adipose tissue, play in driving prostate cancer aggressiveness.

Exosomal circKDM4A Induces CUL4B To Promote Prostate Cancer Cell Malignancy in a miR-338-3p-Dependent Manner

August 12, 2022

[Biochemical Genetics] Scientists reported that exosomes treatment promoted the proliferation, migration and invasion of prostate cancer cells but inhibited apoptosis; however, these effects were attenuated after circKDM4A knockdown.

A Genome-Wide CRISPR-Cas9 Knockout Screen Identifies Novel PARP Inhibitor Resistance Genes in Prostate Cancer

August 12, 2022

[Oncogene] The authors generated multiple knockout populations per gene in C4 and/or LNCaP CRPC cells, which confirmed that loss of PARP1, ARH3, YWHAE, or UBR5 caused olaparib resistance.

Enhancing Nanoparticle Accumulation in Two Dimensional, Three Dimensional, and Xenograft Mouse Cancer Cell Models in the Presence of Docetaxel

August 12, 2022

[Scientific Reports] Researchers explored the use of low concentrations of docetaxel combined with gold nanoparticles in two prostate cancer cell lines in a two-dimensional monolayer, a three-dimensional spheroid, and a mouse xenograft model.

New Diterpenes From the Marine Sponge Spongionella sp. Overcome Drug Resistance in Prostate Cancer by Inhibition of P-Glycoprotein

August 12, 2022

[Scientific Reports] Researchers discovered that spongionellol A and 15,16-dideoxy-15α,17β-dihydroxy-15,17-oxidospongian-16-carboxylate-15,17-diacetate exhibited high activity and selectivity in human prostate cancer cells, including cells resistant to hormonal therapy and docetaxel.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.